Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,501 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06837922RecruitingPhase 3
Study of MG-K10 for moderate to severe asthma
This trial tests a new drug called MG-K10 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if the drug can reduce asthma attacks and improve breathing. You may be able to join if you have had asthma for at least a year, use high-dose inhalers plus another controller medicine, and have had a recent flare-up.
Guangzhou, GuangdongAges 12–75 - NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+ - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT06857942RecruitingPhase 4
Tirzepatide added to ixekizumab for psoriasis and weight issues
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Phoenix, ArizonaAges 18 years+ - NCT06878261RecruitingPhase 3
Tezepelumab for moderate to very severe COPD
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Cullman, AlabamaAges 40–80 - NCT06883305RecruitingPhase 3
Testing tezepelumab for moderate to severe COPD
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
Foley, AlabamaAges 40–80 - NCT06890260Recruiting
Electroacupuncture plus microneedle for allergic rhinitis
This trial tests a 4-week treatment of electroacupuncture combined with microneedle knife for people with moderate to severe allergic rhinitis. It may help reduce symptoms without relying on standard allergy medications.
Hangzhou, ZhejiangAges 18–75 - NCT06903884RecruitingPhase 3
Diquafosol eye drops for moderate-to-severe eye allergy
This trial tests a new eye drop called diquafosol for people with a severe, active eye allergy called vernal keratoconjunctivitis. It aims to see if the drops can calm the allergy and help heal the surface of the eye.
Hong KongAges 6 years+ - NCT06906497RecruitingPhase 4
Lebrikizumab for moderate-to-severe eczema
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
Folsom, CaliforniaAges 18 years+ - NCT06917651RecruitingPhase 3
Study of a new pain medicine for arm or leg injuries in the ER
This trial tests a fast-acting pain pill (sufentanil) placed under the tongue for people with moderate to severe pain from a single arm or leg injury. It aims to see if it works well in the emergency room.
FranceAges 18 years+ - NCT06926192Recruiting
Secukinumab plus surgery for moderate to severe hidradenitis suppurativa
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
Nanjing, JiangsuAges Up to 80 years - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75 - NCT06962020Recruiting
Choosing the best first biologic for moderate to severe colitis
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
Shanxi, Xi'anAges 18–70 - NCT06964269RecruitingPhase 4
Acthar Gel for dry eye and autoimmune disease
This trial tests a new injectable medicine, Acthar Gel, for moderate to severe dry eye and eye pain linked to autoimmune disease. It aims to see if the drug can relieve these symptoms safely.
Nashville, TennesseeAges 18–85 - NCT06967857RecruitingPhase 2
Dexamfetamine for adults with ADHD and depression
This trial tests a study medication (dexamfetamine) for adults who have both ADHD and moderate to severe depression. It aims to see if the medication is safe and helps improve both conditions.
FrankfurtAges 18–65 - NCT06977581RecruitingPhase 2
study of PF-07275315 for moderate-to-severe asthma
This study tests a new medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It is for adults who have had asthma for at least a year, have had recent flare-ups needing steroids, and are not taking other biologic treatments.
Mobile, AlabamaAges 18–70 - NCT06987292Recruiting
Studying IL-17 inhibitors for hidden tendon inflammation in psoriasis
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
Nanjing, JiangsuAges 18 years+ - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Birmingham, AlabamaAges 12 years+ - NCT07008703RecruitingPhase 1/Phase 2
Study of sss40 for cancer bone pain
This trial tests a new injection called sss40 to treat moderate-to-severe pain caused by cancer that has spread to the bones. The goal is to see if it is safe and effective for people whose pain is not being controlled by current treatments.
Zhengzhou, HenanAges 18 years+ - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011524RecruitingPhase 2
Study of CM512 injection for moderate-to-severe asthma
This trial tests a new injection, CM512, for people with moderate-to-severe asthma that is not well controlled with current inhalers. It aims to see if the treatment can reduce asthma attacks and improve symptom control.
Guangzhou, GuangdongAges 18–75 - NCT07017686Recruiting
Reboot Study: Nerve stimulation for rheumatoid arthritis
This study tests a device that sends mild electrical pulses to the vagus nerve in the abdomen to treat rheumatoid arthritis. It is for people whose arthritis has not improved after trying multiple medications.
Fitzroy, VictoriaAges 18–75
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,501 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.